12.5 C
New York
Wednesday, June 23, 2021

Chiasma Inc. (CHMA) stock is on the rise, here’s why it happened

Chiasma Inc. (CHMA) stock gained 20% in the pre-market session on Tuesday, March 23, 2021, after the company posted study data of its CHIASMA OPTIMAL Phase 3 Trial of MYCAPSSA.


5 Stocks Under $10 That Are Poised to Take Off

Investing in stocks under $10 could significantly increase the returns on your portfolio, especially if you pick the right stocks! Within this report you will find 5 top stocks that offer investors huge upside potential and the best bang for their buck.

Add them to your watchlist before they take off!

Get the Top 5 Stocks Now!

Sponsored



Chiasma presented the trial results of MYCAPSSA at the Endocrine Society’s annual meeting, ENDO 2021, being held virtually March 20-23, 2021.

The principal investigator of the trial Susan L. Samson M.D., Ph.D., FRCPC, FACE said that the long-term safety and efficacy data demonstrate that MYCAPSSA maintains insulin-like growth factor 1 (IGF-1) levels in patients with acromegaly who previously required monthly injections for their disease.

Phase 3 clinical trial of CHIASMA OPTIMAL, octreotide capsules duration was nine months and it was conducted under a special agreement with the FDA.

Recent CHMA Financial Announcements

On March 4, 2021, CHMA announced its financial results for the fourth quarter and the year ended December 31, 2020.

Fourth Quarter Financial Highlights

  • CHMA spent $13.6 million in Selling, general and administrative expenses in 4Q of 2020 compared to $5.9 million for the fourth quarter of 2019.
  • Research and development expenses were $4.5 million for the fourth quarter of 2020 compared to $6.4 million for the fourth quarter of 2019
  • The company suffered a net loss of $19.8 million, or $0.32 per basic share in the reported quarter compared to $12.0 million, or $0.29 per basic share for the fourth quarter of 2019.
  • CHMA net product revenue from the sales of MYCAPSSA were approximately $1.0 million for the reported quarter.

Full-Year 2020 Financial Highlights

  • CHMA net product revenue from the sales of MYCAPSSA were approximately $1.1 million for the year ended December 31, 2020.
  • It spent 44.9 million in Selling, general and administrative expenses in 2020 compared to $15.1 million for 2019.
  • Research and development expenses for 2020 were $26.8 million compared to $22.5 million for 2019.
  • The company suffered a net loss of $74.8 million or $1.43 per basic share, compared to $36.3 million, or $1.06 per basic share, for the prior year.
  • As of December 31, 2020, Chiasma had cash, cash equivalents, and marketable securities of $135.4 million

About CHMA

Chiasma is a commercial-stage biopharmaceutical company focused on developing and commercializing oral therapies to improve the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases. The company was founded in 2001 and is based in Needham, Massachusetts, United States. CHMA used its Transient Permeability Enhancer (TPE) technology platform to develop oral medications that are currently available only as injections.

The company is lead by Raj Kannan who is the president and CEO of the company.

Conclusion:

The recent positive trial 3 results of MYCAPSSA make CHMA stock more attractive to the investors and its price can go up in the coming days.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Related Articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest Articles

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

100% free. stop anytime no spam

Get The Best Stocks To Trade Every Day!

Join now to get the Newsheater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.